Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Novel US FDA Approvals Could Rebound In 2017: 40+ Candidates Already Under Review

Novel approvals by US FDA in 2017 could easily surpass the 28 agents approved by the agency's drug and biologics centers in 2016. The big question is whether last year's spike in complete response letters was an anomaly or the start of a trend.

Approvals Review Pathway Regulation

Cyclacel CEO Explains How Sapacitabine Might Get Cleared For AML, Despite Phase III Failure

The company will talk to regulators in the US and Europe to see if the drug could be considered in elderly patients with low baseline peripheral white blood cells, who fared better than others in the failed SEAMLESS study.

Clinical Trials Regulation Cancer

ICER Revising Drug Review Criteria, Will Use Net Prices, Broad Evidence Base

Proposed updates to group’s cost effectiveness evaluations will guide reviews during 2017-2019. Ultra-orphan drug will be assessed with different standards.

Cost Effectiveness Pricing Strategies Reimbursement

Busy In-Tray Awaits New EFPIA Boss Nathalie Moll

Nathalie Moll, secretary general of biotech industry body EuropaBio, is to be the next director general of EFPIA, the federation that represents the R&D-based pharmaceutical industry in Europe. With issues such as the forthcoming Brexit negotiations, the EU’s inquiry into medicines access and pricing, and the implementation of the new Clinical Trials Regulation, EFPIA’s new leader will have a lot of weighty dossiers to deal with.

Leadership Regulation Market Access
Advertisement


FDA Performance Tracker
For more on the FDA Performance Tracker, click here.

Policy & Regulation Explore this Topic

Set Alert for Policy & Regulation

Pfizer Warning Letter Trips Up Sandoz/Momenta’s Expected Glatopa Launch

Sandoz/Momenta’s generic of Teva’s 40 mg Copaxone appeared imminent – until apparently unrelated FDA warning letter regarding contract manufacturer Pfizer’s McPherson, Kan., plant put review on hold.

Manufacturing Quality Approvals

Latest From Regulation

Adverse Event Assessment In India Gets Harvard-Built Tool; Will Increased Trial Activity Follow?

Against backdrop of subdued trial activity in the country and concerns about injury compensation, Indian Society for Clinical Research and Harvard's MRCT Centre offer a portal to facilitate a more objective assessment of causality of serious adverse events.

Drug Safety Clinical Trials

ICH To Fix Inconsistencies With RCTs, Address Use Of Alternate Designs And Data Sources

The International Council for Harmonisation has proposed major changes to its good clinical practice requirements in a bid to allay concerns about the problems they pose in conducting well-designed randomized trials. The revised GCP framework would also address the increasing diversity of clinical trial designs and data sources.

Regulation Clinical Trials

FDA's NDA And BLA Approvals: Ganciclovir

Original new drugs and biologics recently approved by US FDA.

Approvals Regulation

Latest From Policy

Bayer CEO On Europe's 'Identity Crisis'

The UK's decision to leave the European Union and a change in global politics that has prompted emotions to get in the way of facts are the catalysts for Europe's current identity crisis, says Bayer chief Werner Baumann. During the company's annual financial results presentation in Leverkusen, Germany, the CEO also called on European regulators to better protect innovation during times of political uncertainty.

Brexit Policy

Ovarian Cancer Drugs Will Get ICER Review As Olaparib's Maintenance Indication Looms

PARP inhibitors from Tesaro, Clovis, and AstraZeneca have been tentatively chosen for the evaluation.

Pricing Strategies Reimbursement

Rx Spending Stands Out In CMS Projections – As Slowing Down

Pharmaceutical industry’s message on overall drug spending trends is getting some timely support from the Center for Medicare and Medicaid Services’ annual national health expenditure projections.

Pricing Debate Policy

Clinical / R&D Explore this Topic

Set Alert for Clinical R&D

Latest From Research & Development

Adverse Event Assessment In India Gets Harvard-Built Tool; Will Increased Trial Activity Follow?

Against backdrop of subdued trial activity in the country and concerns about injury compensation, Indian Society for Clinical Research and Harvard's MRCT Centre offer a portal to facilitate a more objective assessment of causality of serious adverse events.

Drug Safety Clinical Trials

Belgium To Test Parallel Review Of Clinical Trial Dossiers Ahead Of New Regulation

Belgium is following the footsteps of Germany and France by launching a pilot to develop and test procedures for the coming EU Clinical Trial Regulation, which requires national competent authorities and ethics committees to evaluate trial dossiers in parallel and to issue a consolidated single decision within short timelines.

Regulation Clinical Trials

Intercept's Revised NASH Trial Improves Prospects

The pivotal REGENERATE study of Ocaliva now can succeed if either of two co-primary endpoints is achieved. Intercept also will use a new "objective" definition of NASH resolution in the study.

Clinical Trials Research & Development

Commercial Explore this Topic

Set Alert for Commercial

Latest From Commercial

Cost Versus Value: Earnings Calls Spotlight US Pricing Reforms

Pink Sheet has scoured big pharma annual results presentations to gauge the industry's reactions and concerns around the increasingly tough US drug pricing environment and proposed changes to the Affordable Care Act under the new Trump administration.

Pricing Debate Pricing Strategies

J&J Outlines Pricing Transparency Plan, Will Others Follow?

CEO Gorsky describes J&J’s approach to drug pricing and pledges to provide more detail in an annual transparency report. Investor pressure regarding the pricing debate continued during the Novartis earnings call. Value arguments expected to dominate pharma’s message.

Pricing Debate Sales & Earnings

New Policy Fund Reflects Korea’s Commitment To Health Biotech

South Korea's plan to create a policy fund to support new growth engine industries seems to reaffirm the government's unwavering commitment to nurture the biotech and health care sectors despite the ongoing political chaos in the country.

South Korea Financing

Manufacturing Explore this Topic

Set Alert for Manufacturing

Latest From Manufacturing

Quality Regulatory Updates In Brief: ICH, EMA, MHRA and FDA

ICH updates progress made on quality guidelines; EMA talks combination products; UK MHRA report sheds light on GMP deficiencies; MHRA official describes compliance escalation; FDA guides microbiology reviewers through Common Technical Document; FDA OKs reliance on non-USP compendia in applications.

Quality Manufacturing

A Drag On Drugs? Trump’s Tariffs Could Raise Costs, Particularly For Generics

Drug makers remain mum on Trump tariffs despite worries that older generics could get squeezed. Landmark WHO study is adamant that tariffs should never be imposed on medicines.

Manufacturing Policy

How US Tax Plan Could Affect Global Pharma Manufacturing Networks

Allergan, Pfizer, Bristol-Myers Squibb, AbbVie, GSK, Sanofi and Roche showed glimpses in recent earnings calls of potential impacts on their global manufacturing networks from a US plan to legislate border-adjusted tax cuts. But there was not a word about President Trump’s threat of tariffs.

Manufacturing Policy

Consumer / OTC Drugs Explore this Topic

Set Alert for Consumer OTC Drugs

Latest From Consumer

Bayer Plans 19 Consumer Product Launches To Revive Sluggish Sales

Bayer consumer readies 19-product pipeline for 2017 as it works to increase sales of brands including Coppertone and Dr. Scholl’s brands that have been sluggish since being acquired from Merck & Co.

Consumer Advertising, Marketing & Sales

Is Takeda's Consumer Unit 'Agile' Enough To Stretch Outside Japan?

Takeda says spinning off its consumer product portfolio into a wholly owned and independent subsidiary will boost its profile in the sector, but all signs continue to point to the firm's Rx operations as its predominant revenue drivers.

Consumer Japan

Consumer Health Weekly Trademark Review Feb. 14, 2017

OTC drug, personal care product and nutritional supplement trademark filings compiled from Official Gazette of the U.S. Patent and Trademark Office, Class 3 – Cosmetics and Cleaning Preps; and Class 5 – Pharmaceuticals.

Consumer Trademarks
UsernamePublicRestriction

Register